SCIENTIFIC PROGRAMME
SESSION I
HOW I TREAT
SMOLDERING MYELOMA
(SMM)
SESSION II
HOW I TREAT NEWLY
DIAGNOSED MULTIPLE
MYELOMA
SESSION III
FROM RISK
STRATIFICATION TO
RISK-BASED THERAPY?
DEBATE 1
SHOULD WE USE MRD
TESTING TO DETERMINE
THERAPY IN MULTIPLE
MYELOMA?
DEBATE 2
IS THERE A FUTURE ROLE
OF AUTOLOGOUS STEM
CELL TRANSPLANTATION?
SESSION IV
HOW I TREAT RELAPSED
MULTIPLE MYELOMA
DEBATE 3
SHOULD EVERY PATIENT
RECEIVE DARATUMUMAB
IN FIRST LINE?
ROUNDTABLE
MULTIPLE MYELOMA
FROM THE PERSPECTIVE
OF FDA/EMEA AND
FOUNDATIONS
SESSION V
YOU CAN’T BE IMMUNE
FOR IMMUNE THERAPY
ANYMORE
SESSION VI
OTHER PLASMA CELL
DYSCRASIAS
KEYNOTE LECTURES
THE FUTURE OF
MULTIPLE MYELOMA
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
ABSTRACTS SELECTED
AS POSTERS
DISCLOSURES
POSTER 33
A DESCRIPTIVE COST-ANALYSIS OF MYX.1/MCRN003, A PHASE 2 CLINICAL TRIAL
EVALUATING HIGH-DOSE WEEKLY CARFILZOMIB, CYCLOPHOSPHAMIDE, AND
DEXAMETHASONE IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Bethany E. Monteith1, Christopher P. Venner2, Matthew C. Cheung3, Joe L. Pater1, Lois Shepherd1,
Harriet Richardson1, Donna Reece4, Engin Gul5, Marc Lalancette6, Vincent Castonguay7, Vishal Kukreti3,
Rodger Tiedemann3, Chai Phua8, Sita Bhella3, Jill Dudebout1, Max Sherry1, Hope Yen1, Bingshu E.
Chen1 and Annette E. Hay1
(1)Queen's University, Kingston, Canada
(2)Cross Cancer Institute, University of Alberta, Edmonton, Canada
(3)University of Toronto, Toronto, Canada
(4)Princess Margaret Hospital, Toronto, Canada
(5)Canadian Myeloma Research Network, Toronto, Canada
(6)Université Laval, Quebec City, Canada
(7)Université Laval, Quebec City, Canada
(8)Western University, London, Canada
Background
The prevalence of multiple myeloma is increasing and there is a need to evaluate the associated
escalating therapy costs(1). The MYX.1 phase II trial showed that high-dose weekly carfilzomib,
cyclophosphamide, and dexamethasone (wKCD) is efficacious in relapsed and refractory disease (2,3).
We conducted a descriptive cost analysis, from the perspective of the Canadian public healthcare
system, using trial data.
Methods
The primary outcome was the mean total cost per patient. Resource utilization data were collected
from all 75 patients enrolled in the MYX.1 trial over a trial time horizon. Costs are presented in
Canadian dollars (2020).
Results
The cost of treatment was calculated from the time of patient enrollment until the time of the second
data lock in June 2019. The mean total cost per patient was $203,336.08 (range $17,891.27 –
$505,583.55) Canadian dollars (CAD, where 1 CAD = 0.65 Euro (EUR)). The median number of cycles
was 15. The mean cost per patient per cycle was $14,081.45. The predominant cost driver was the cost
of chemotherapy accounting for an average of $179,332.78 per patient or $12,419.17 per patient per
cycle. Carfilzomib acquisition accounted for the majority of chemotherapy costs – $162,471.65 total
per patient or $11,251.50 per patient per cycle. Fifty-six percent (56%) of patients had at least one
hospitalization during the trial period with an average cost of $12,657.86 per hospitalization. The
average cost to treat each patient with thrombotic microangiopathy (TMA) was $18,863.32 including
the cost of hospitalizations and therapeutic plasma exchange.
Conclusions
High-dose wKCD is an active triplet regimen for RRMM associated with reduced total cost compared
with twice weekly regimens.